Atomo Diagnostics Limited (ASX: AT1) has announced the successful placement of the remaining $416,611.77 shortfall from its Share Purchase Plan (SPP). Atomo, an Australian-headquartered medical device company supplying unique, integrated rapid diagnostic test (RDT) devices to the global diagnostic market, allocated the shortfall to institutional and sophisticated investors following inbound interest. This placement follows a recent announcement of an order from Lumos Diagnostics (ASX: LDX) for Atomo’s Pascal cassettes, intended to support the scale-up of FebriDx® demand in the US market.
Previously, Atomo Diagnostics raised $272,387.50 through its SPP, allotting 14,723,685 shares to existing shareholders. An additional 16,810,814 shares were placed to investors who participated in the July Shortfall Placement, which settled on 24 July 2025, raising $311,000. The final Shortfall Placement, approved by shareholders on 23 June 2025, will issue 22,519,555 shares at $0.0185 per share and 22,519,555 options with an exercise price of $0.04, expiring 14 August 2028, on terms consistent with the SPP. Allotment of the shortfall securities is anticipated on Thursday, 14 August 2025.
The Shortfall Placement was managed by Joint Lead Managers Bay Financial Pty Ltd and GBA Capital Pty Ltd, who will receive fees of 6% of the funds placed. According to the company, the funds raised from this placement will be used to meet general working capital requirements and fund ongoing business objectives.
John Kelly, Managing Director & CEO & Interim Chair of Atomo Diagnostics, expressed gratitude to both existing and new shareholders for their participation in the company’s fundraising initiatives, including the Placement, Share Purchase Plan, and Shortfall Placement, stating that the additional capital positions the company strongly for future operational activities.
